newsfilter
← Latest News
GlobeNewswire·

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

  • China SXT Pharmaceuticals Inc. entered a definitive securities purchase agreement with institutional investors for a registered direct offering of 4,500,000 units.
  • Each unit consists of one Class A ordinary share & one common warrant sold at $2.00 per unit.
  • The warrants have an exercise price of $3.20 per share, are immediately exercisable, & expire one year after issuance.
  • Expected aggregate gross proceeds are approximately $9 million before deducting placement agent fees & other offering expenses.
  • The transaction is expected to close on or about July 24, 2025, subject to customary closing conditions.
  • Univest Securities, LLC is acting as the sole placement agent for the offering.
  • The offering is made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) that became effective on December 1, 2025.
  • Final prospectus supplements & accompanying prospectus will be filed with the SEC & available at www.sec.gov or via Univest Securities, LLC.